Cell and Gene Therapy is an established and rapidly growing field that depends on viral vectors as a critical raw material. The evolving Vector Crisis, shortages acutely felt by today’s late-stage market, is threatening to derail the significant gains made in the last four decades. VPI has a uniquely experienced team, with a patent-protected technological solution, and a differentiating business plan that is a unique fit for today's market.